Entering text into the input field will update the search result below

Cellectis to get €40M from European Investment Bank to support CAR T-cell development

Dec. 28, 2022 5:17 PM ETCellectis S.A. (CLLS)By: Anuron Mitra, SA News Editor

Exterior view of headquarters of of the European Investment Bank (EIB)

Alexandros Michailidis/iStock Editorial via Getty Images

  • Clinical-stage biotech Cellectis (NASDAQ:CLLS) on Wednesday said it had entered into a €40M credit agreement with the European Investment Bank (EIB).
  • CLLS will use the credit facility to support the development of its CAR T-cell product candidates, the company said in a statement.
  • The credit facility will consist of three tranches of €20M, €15M and €5M, each redeemable in fine in six years.
  • The EIB's financing is part of its strategy to provide funding to biotech companies developing therapies for significant unmet medical needs.
  • U.S.-listed shares of CLLS earlier closed -1.6% at $1.85.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Cellectis S.A.
Innate Pharma S.A.
Harpoon Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
Mesoblast Limited
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.